{"frames":[{"target":{"name":"Craft","spans":[{"start":0,"end":1,"text":"Science"}]},"annotationSets":[{"rank":0,"score":11.691366466170551,"frameElements":[]}]},{"target":{"name":"Medical_specialties","spans":[{"start":2,"end":3,"text":"medicine"}]},"annotationSets":[{"rank":0,"score":4.571156479647906,"frameElements":[{"name":"Specialty","spans":[{"start":0,"end":3,"text":"Science translational medicine"}]}]}]}],"tokens":["Science","translational","medicine","."]}
{"frames":[{"target":{"name":"Categorization","spans":[{"start":7,"end":8,"text":"defined"}]},"annotationSets":[{"rank":0,"score":38.50022466264327,"frameElements":[{"name":"Item","spans":[{"start":8,"end":9,"text":"ratio"}]}]}]},{"target":{"name":"Building_subparts","spans":[{"start":24,"end":25,"text":"cells"}]},"annotationSets":[{"rank":0,"score":16.222583684776563,"frameElements":[{"name":"Type","spans":[{"start":23,"end":24,"text":"T"}]},{"name":"Building_part","spans":[{"start":24,"end":25,"text":"cells"}]}]}]}],"tokens":["Immunotherapy","of","non-Hodgkin","'s","lymphoma","with","a","defined","ratio","of","CD8","-LRB-","+","-RRB-","and","CD4","-LRB-","+","-RRB-","CD19-specific","chimeric","antigen","receptor-modified","T","cells","."]}
{"frames":[{"target":{"name":"Causation","spans":[{"start":30,"end":32,"text":"because of"}]},"annotationSets":[{"rank":0,"score":81.17564826250795,"frameElements":[{"name":"Cause","spans":[{"start":19,"end":25,"text":"factors that affect toxicity and efficacy"}]},{"name":"Effect","spans":[{"start":32,"end":44,"text":"differences in lymphodepletion and heterogeneity of CAR-T cells administered to individual patients"}]}]}]},{"target":{"name":"Vehicle","spans":[{"start":5,"end":6,"text":"CAR"}]},"annotationSets":[{"rank":0,"score":29.04111033055632,"frameElements":[{"name":"Vehicle","spans":[{"start":5,"end":6,"text":"CAR"}]}]}]},{"target":{"name":"Building_subparts","spans":[{"start":9,"end":10,"text":"cells"}]},"annotationSets":[{"rank":0,"score":16.769385121787654,"frameElements":[{"name":"Building_part","spans":[{"start":9,"end":10,"text":"cells"}]}]}]},{"target":{"name":"Being_obligated","spans":[{"start":10,"end":11,"text":"have"}]},"annotationSets":[{"rank":0,"score":17.447236745952107,"frameElements":[{"name":"Responsible_party","spans":[{"start":0,"end":10,"text":"CD19-specific chimeric antigen receptor -LRB- CAR -RRB- -modified T cells"}]}]}]},{"target":{"name":"Intentionally_act","spans":[{"start":12,"end":13,"text":"activity"}]},"annotationSets":[{"rank":0,"score":67.7835441044953,"frameElements":[{"name":"Agent","spans":[{"start":0,"end":10,"text":"CD19-specific chimeric antigen receptor -LRB- CAR -RRB- -modified T cells"}]}]}]},{"target":{"name":"Building_subparts","spans":[{"start":15,"end":16,"text":"cell"}]},"annotationSets":[{"rank":0,"score":15.614655075421835,"frameElements":[{"name":"Building_part","spans":[{"start":15,"end":16,"text":"cell"}]}]}]},{"target":{"name":"Contingency","spans":[{"start":19,"end":20,"text":"factors"}]},"annotationSets":[{"rank":0,"score":21.912032041445645,"frameElements":[{"name":"Determinant","spans":[{"start":19,"end":20,"text":"factors"}]}]}]},{"target":{"name":"Objective_influence","spans":[{"start":21,"end":22,"text":"affect"}]},"annotationSets":[{"rank":0,"score":36.43955071329974,"frameElements":[{"name":"Influencing_situation","spans":[{"start":19,"end":20,"text":"factors"}]}]}]},{"target":{"name":"Difficulty","spans":[{"start":27,"end":28,"text":"difficult"}]},"annotationSets":[{"rank":0,"score":35.13110096781439,"frameElements":[{"name":"Activity","spans":[{"start":28,"end":44,"text":"to define because of differences in lymphodepletion and heterogeneity of CAR-T cells administered to individual patients"}]}]}]},{"target":{"name":"Communicate_categorization","spans":[{"start":29,"end":30,"text":"define"}]},"annotationSets":[{"rank":0,"score":38.54603164855904,"frameElements":[{"name":"Speaker","spans":[{"start":19,"end":25,"text":"factors that affect toxicity and efficacy"}]},{"name":"Item","spans":[{"start":31,"end":44,"text":"of differences in lymphodepletion and heterogeneity of CAR-T cells administered to individual patients"}]}]}]},{"target":{"name":"Similarity","spans":[{"start":32,"end":33,"text":"differences"}]},"annotationSets":[{"rank":0,"score":67.43659655385869,"frameElements":[]}]},{"target":{"name":"Natural_features","spans":[{"start":36,"end":37,"text":"heterogeneity"}]},"annotationSets":[{"rank":0,"score":35.65687518940172,"frameElements":[{"name":"Locale","spans":[{"start":36,"end":37,"text":"heterogeneity"}]}]}]},{"target":{"name":"Building_subparts","spans":[{"start":39,"end":40,"text":"cells"}]},"annotationSets":[{"rank":0,"score":21.417931862399577,"frameElements":[{"name":"Building_part","spans":[{"start":39,"end":40,"text":"cells"}]}]}]},{"target":{"name":"Leadership","spans":[{"start":40,"end":41,"text":"administered"}]},"annotationSets":[{"rank":0,"score":61.00251588094401,"frameElements":[{"name":"Leader","spans":[{"start":39,"end":40,"text":"cells"}]}]}]},{"target":{"name":"People","spans":[{"start":42,"end":43,"text":"individual"}]},"annotationSets":[{"rank":0,"score":28.114055896357883,"frameElements":[{"name":"Person","spans":[{"start":42,"end":43,"text":"individual"}]}]}]}],"tokens":["CD19-specific","chimeric","antigen","receptor","-LRB-","CAR","-RRB-","-modified","T","cells","have","antitumor","activity","in","B","cell","malignancies",",","but","factors","that","affect","toxicity","and","efficacy","have","been","difficult","to","define","because","of","differences","in","lymphodepletion","and","heterogeneity","of","CAR-T","cells","administered","to","individual","patients","."]}
{"frames":[{"target":{"name":"Intentionally_act","spans":[{"start":1,"end":2,"text":"conducted"}]},"annotationSets":[{"rank":0,"score":70.68076819705657,"frameElements":[{"name":"Act","spans":[{"start":7,"end":10,"text":"CD19 CAR-T cells"}]},{"name":"Agent","spans":[{"start":0,"end":1,"text":"We"}]}]}]},{"target":{"name":"Trial","spans":[{"start":4,"end":5,"text":"trial"}]},"annotationSets":[{"rank":0,"score":44.56066109754403,"frameElements":[{"name":"Defendant","spans":[{"start":3,"end":4,"text":"clinical"}]}]}]},{"target":{"name":"Building_subparts","spans":[{"start":9,"end":10,"text":"cells"}]},"annotationSets":[{"rank":0,"score":18.293726576958385,"frameElements":[{"name":"Building_part","spans":[{"start":9,"end":10,"text":"cells"}]}]}]},{"target":{"name":"Manufacturing","spans":[{"start":11,"end":12,"text":"manufactured"}]},"annotationSets":[{"rank":0,"score":79.05155383444719,"frameElements":[{"name":"Resource","spans":[{"start":12,"end":17,"text":"from defined T cell subsets"}]},{"name":"Product","spans":[{"start":7,"end":10,"text":"CD19 CAR-T cells"}]}]}]},{"target":{"name":"Categorization","spans":[{"start":13,"end":14,"text":"defined"}]},"annotationSets":[{"rank":0,"score":37.77039890350597,"frameElements":[{"name":"Item","spans":[{"start":14,"end":15,"text":"T"}]}]}]},{"target":{"name":"Building_subparts","spans":[{"start":15,"end":16,"text":"cell"}]},"annotationSets":[{"rank":0,"score":15.637487934130435,"frameElements":[{"name":"Building_part","spans":[{"start":15,"end":16,"text":"cell"}]}]}]},{"target":{"name":"Weapon","spans":[{"start":16,"end":17,"text":"subsets"}]},"annotationSets":[{"rank":0,"score":55.99082315207133,"frameElements":[{"name":"Weapon","spans":[{"start":16,"end":17,"text":"subsets"}]}]}]},{"target":{"name":"Leadership","spans":[{"start":18,"end":19,"text":"administered"}]},"annotationSets":[{"rank":0,"score":61.619093348426595,"frameElements":[{"name":"Leader","spans":[{"start":7,"end":10,"text":"CD19 CAR-T cells"}]},{"name":"Governed","spans":[{"start":19,"end":22,"text":"in a 1"}]}]}]},{"target":{"name":"Building_subparts","spans":[{"start":35,"end":36,"text":"cells"}]},"annotationSets":[{"rank":0,"score":21.42420358713812,"frameElements":[{"name":"Building_part","spans":[{"start":35,"end":36,"text":"cells"}]}]}]},{"target":{"name":"People_by_age","spans":[{"start":38,"end":39,"text":"adults"}]},"annotationSets":[{"rank":0,"score":30.410127557496594,"frameElements":[{"name":"Person","spans":[{"start":38,"end":39,"text":"adults"}]}]}]},{"target":{"name":"Building_subparts","spans":[{"start":44,"end":45,"text":"cell"}]},"annotationSets":[{"rank":0,"score":15.476238859703482,"frameElements":[{"name":"Building_part","spans":[{"start":44,"end":45,"text":"cell"}]}]}]},{"target":{"name":"Medical_conditions","spans":[{"start":61,"end":62,"text":"Flu"}]},"annotationSets":[{"rank":0,"score":36.410903792498374,"frameElements":[{"name":"Ailment","spans":[{"start":61,"end":62,"text":"Flu"}]}]}]}],"tokens":["We","conducted","a","clinical","trial","in","which","CD19","CAR-T","cells","were","manufactured","from","defined","T","cell","subsets","and","administered","in","a","1",":","1","CD4","-LRB-","+","-RRB-","/CD8","-LRB-","+","-RRB-","ratio","of","CAR-T","cells","to","32","adults","with","relapsed","and/or","refractory","B","cell","non-Hodgkin","'s","lymphoma","after","cyclophosphamide","-LRB-","Cy","-RRB-","-based","lymphodepletion","chemotherapy","with","or","without","fludarabine","-LRB-","Flu","-RRB-","."]}
{"frames":[{"target":{"name":"Receiving","spans":[{"start":2,"end":3,"text":"received"}]},"annotationSets":[{"rank":0,"score":48.93859479047083,"frameElements":[{"name":"Theme","spans":[{"start":3,"end":5,"text":"Cy/Flu lymphodepletion"}]}]}]},{"target":{"name":"Change_position_on_a_scale","spans":[{"start":6,"end":7,"text":"increased"}]},"annotationSets":[{"rank":0,"score":119.58444835567954,"frameElements":[]}]},{"target":{"name":"Building_subparts","spans":[{"start":8,"end":9,"text":"cell"}]},"annotationSets":[{"rank":0,"score":15.588146345402848,"frameElements":[{"name":"Building_part","spans":[{"start":8,"end":9,"text":"cell"}]}]}]},{"target":{"name":"Expansion","spans":[{"start":9,"end":10,"text":"expansion"}]},"annotationSets":[{"rank":0,"score":36.14996345281381,"frameElements":[{"name":"Item","spans":[{"start":8,"end":9,"text":"cell"}]}]}]},{"target":{"name":"Process_continue","spans":[{"start":11,"end":12,"text":"persistence"}]},"annotationSets":[{"rank":0,"score":35.38287833645287,"frameElements":[{"name":"Event","spans":[{"start":0,"end":5,"text":"Patients who received Cy/Flu lymphodepletion"}]}]}]},{"target":{"name":"Position_on_a_scale","spans":[{"start":14,"end":15,"text":"higher"}]},"annotationSets":[{"rank":0,"score":20.22418547454197,"frameElements":[{"name":"Item","spans":[{"start":15,"end":16,"text":"response"}]},{"name":"Value","spans":[{"start":14,"end":15,"text":"higher"}]}]}]},{"target":{"name":"Response","spans":[{"start":15,"end":16,"text":"response"}]},"annotationSets":[{"rank":0,"score":40.75731363062538,"frameElements":[]}]},{"target":{"name":"Frequency","spans":[{"start":16,"end":17,"text":"rates"}]},"annotationSets":[{"rank":0,"score":35.896341971952296,"frameElements":[]}]},{"target":{"name":"Cardinal_numbers","spans":[{"start":18,"end":19,"text":"50"}]},"annotationSets":[{"rank":0,"score":24.93691627541174,"frameElements":[{"name":"Number","spans":[{"start":18,"end":19,"text":"50"}]}]}]},{"target":{"name":"Process_completed_state","spans":[{"start":20,"end":21,"text":"complete"}]},"annotationSets":[{"rank":0,"score":2.3230634099918763,"frameElements":[{"name":"Process","spans":[{"start":21,"end":22,"text":"remission"}]}]}]},{"target":{"name":"Clothing","spans":[{"start":28,"end":29,"text":"overall"}]},"annotationSets":[{"rank":0,"score":35.66047233913659,"frameElements":[]}]},{"target":{"name":"Response","spans":[{"start":29,"end":30,"text":"response"}]},"annotationSets":[{"rank":0,"score":40.75731363062538,"frameElements":[]}]},{"target":{"name":"Frequency","spans":[{"start":30,"end":31,"text":"rate"}]},"annotationSets":[{"rank":0,"score":26.43468156375527,"frameElements":[]}]},{"target":{"name":"Receiving","spans":[{"start":38,"end":39,"text":"received"}]},"annotationSets":[{"rank":0,"score":47.219701591245375,"frameElements":[{"name":"Recipient","spans":[{"start":36,"end":37,"text":"patients"}]},{"name":"Theme","spans":[{"start":39,"end":41,"text":"Cy-based lymphodepletion"}]}]}]},{"target":{"name":"Medical_conditions","spans":[{"start":42,"end":43,"text":"Flu"}]},"annotationSets":[{"rank":0,"score":33.990407211421214,"frameElements":[{"name":"Ailment","spans":[{"start":42,"end":43,"text":"Flu"}]}]}]},{"target":{"name":"Cardinal_numbers","spans":[{"start":48,"end":49,"text":"50"}]},"annotationSets":[{"rank":0,"score":25.028303666119506,"frameElements":[{"name":"Number","spans":[{"start":48,"end":49,"text":"50"}]}]}]}],"tokens":["Patients","who","received","Cy/Flu","lymphodepletion","had","increased","CAR-T","cell","expansion","and","persistence",",","and","higher","response","rates","-LSB-","50","%","complete","remission","-LRB-","CR","-RRB-",",","72","%","overall","response","rate","-LRB-","ORR","-RRB-","-RSB-","than","patients","who","received","Cy-based","lymphodepletion","without","Flu","-LRB-","8","%","CR",",","50","%","ORR","-RRB-","."]}
{"frames":[{"target":{"name":"Frequency","spans":[{"start":2,"end":3,"text":"rate"}]},"annotationSets":[{"rank":0,"score":26.460536368555918,"frameElements":[]}]},{"target":{"name":"Communicate_categorization","spans":[{"start":5,"end":6,"text":"treated"}]},"annotationSets":[{"rank":0,"score":40.43664947752783,"frameElements":[{"name":"Speaker","spans":[{"start":0,"end":3,"text":"The CR rate"}]},{"name":"Item","spans":[{"start":6,"end":8,"text":"with Cy/Flu"}]}]}]},{"target":{"name":"Quantity","spans":[{"start":12,"end":13,"text":"dose"}]},"annotationSets":[{"rank":0,"score":21.5287179091044,"frameElements":[{"name":"Quantity","spans":[{"start":12,"end":13,"text":"dose"}]}]}]}],"tokens":["The","CR","rate","in","patients","treated","with","Cy/Flu","at","the","maximally","tolerated","dose","was","64","%","-LRB-","82","%","ORR",";","n","=","11","-RRB-","."]}
{"frames":[{"target":{"name":"Objective_influence","spans":[{"start":3,"end":4,"text":"effects"}]},"annotationSets":[{"rank":0,"score":38.831208194545454,"frameElements":[{"name":"Influencing_situation","spans":[{"start":4,"end":35,"text":"of an immune response to the murine single-chain variable fragment component of the CAR , which limited CAR-T cell expansion and clinical efficacy in patients who received Cy-based lymphodepletion without Flu"}]}]}]},{"target":{"name":"Response","spans":[{"start":7,"end":8,"text":"response"}]},"annotationSets":[{"rank":0,"score":42.56506965562855,"frameElements":[{"name":"Trigger","spans":[{"start":8,"end":35,"text":"to the murine single-chain variable fragment component of the CAR , which limited CAR-T cell expansion and clinical efficacy in patients who received Cy-based lymphodepletion without Flu"}]}]}]},{"target":{"name":"Contingency","spans":[{"start":12,"end":13,"text":"variable"}]},"annotationSets":[{"rank":0,"score":13.283703943858736,"frameElements":[]}]},{"target":{"name":"Part_piece","spans":[{"start":13,"end":14,"text":"fragment"}]},"annotationSets":[{"rank":0,"score":7.834877567767044,"frameElements":[{"name":"Substance","spans":[{"start":13,"end":14,"text":"fragment"}]}]}]},{"target":{"name":"Ingredients","spans":[{"start":14,"end":15,"text":"component"}]},"annotationSets":[{"rank":0,"score":20.717526937418455,"frameElements":[{"name":"Material","spans":[{"start":14,"end":15,"text":"component"}]},{"name":"Product","spans":[{"start":13,"end":14,"text":"fragment"}]}]}]},{"target":{"name":"Vehicle","spans":[{"start":17,"end":18,"text":"CAR"}]},"annotationSets":[{"rank":0,"score":30.71619877376796,"frameElements":[{"name":"Vehicle","spans":[{"start":17,"end":18,"text":"CAR"}]}]}]},{"target":{"name":"Building_subparts","spans":[{"start":22,"end":23,"text":"cell"}]},"annotationSets":[{"rank":0,"score":15.476534988063904,"frameElements":[{"name":"Building_part","spans":[{"start":22,"end":23,"text":"cell"}]}]}]},{"target":{"name":"Expansion","spans":[{"start":23,"end":24,"text":"expansion"}]},"annotationSets":[{"rank":0,"score":36.038352095474856,"frameElements":[{"name":"Item","spans":[{"start":22,"end":23,"text":"cell"}]}]}]},{"target":{"name":"Receiving","spans":[{"start":30,"end":31,"text":"received"}]},"annotationSets":[{"rank":0,"score":48.229847874266405,"frameElements":[{"name":"Recipient","spans":[{"start":28,"end":29,"text":"patients"}]},{"name":"Donor","spans":[{"start":33,"end":35,"text":"without Flu"}]},{"name":"Theme","spans":[{"start":31,"end":33,"text":"Cy-based lymphodepletion"}]}]}]},{"target":{"name":"Medical_conditions","spans":[{"start":34,"end":35,"text":"Flu"}]},"annotationSets":[{"rank":0,"score":35.61039114408429,"frameElements":[{"name":"Ailment","spans":[{"start":34,"end":35,"text":"Flu"}]}]}]}],"tokens":["Cy/Flu","minimized","the","effects","of","an","immune","response","to","the","murine","single-chain","variable","fragment","component","of","the","CAR",",","which","limited","CAR-T","cell","expansion","and","clinical","efficacy","in","patients","who","received","Cy-based","lymphodepletion","without","Flu","."]}
{"frames":[{"target":{"name":"Releasing","spans":[{"start":2,"end":3,"text":"release"}]},"annotationSets":[{"rank":0,"score":21.46874274556108,"frameElements":[{"name":"Theme","spans":[{"start":1,"end":2,"text":"cytokine"}]}]}]},{"target":{"name":"Medical_conditions","spans":[{"start":3,"end":4,"text":"syndrome"}]},"annotationSets":[{"rank":0,"score":30.816157706705255,"frameElements":[{"name":"Ailment","spans":[{"start":3,"end":4,"text":"syndrome"}]}]}]},{"target":{"name":"Cardinal_numbers","spans":[{"start":11,"end":12,"text":"3"}]},"annotationSets":[{"rank":0,"score":32.19920381481266,"frameElements":[{"name":"Number","spans":[{"start":11,"end":12,"text":"3"}]},{"name":"Entity","spans":[{"start":12,"end":13,"text":"neurotoxicity"}]}]}]},{"target":{"name":"Statement","spans":[{"start":14,"end":15,"text":"observed"}]},"annotationSets":[{"rank":0,"score":104.46668473975055,"frameElements":[{"name":"Message","spans":[{"start":0,"end":13,"text":"Severe cytokine release syndrome -LRB- sCRS -RRB- and grade > = 3 neurotoxicity"}]}]}]},{"target":{"name":"Quantity","spans":[{"start":21,"end":22,"text":"all"}]},"annotationSets":[{"rank":0,"score":26.972754456495856,"frameElements":[{"name":"Quantity","spans":[{"start":21,"end":22,"text":"all"}]},{"name":"Individuals","spans":[{"start":22,"end":23,"text":"patients"}]}]}]}],"tokens":["Severe","cytokine","release","syndrome","-LRB-","sCRS","-RRB-","and","grade",">","=","3","neurotoxicity","were","observed","in","13","and","28","%","of","all","patients",",","respectively","."]}
{"frames":[{"target":{"name":"Cardinal_numbers","spans":[{"start":3,"end":4,"text":"one"}]},"annotationSets":[{"rank":0,"score":32.901411929899815,"frameElements":[{"name":"Number","spans":[{"start":3,"end":4,"text":"one"}]},{"name":"Entity","spans":[{"start":4,"end":16,"text":"day after CAR-T cell infusion , correlated with subsequent sCRS and neurotoxicity"}]}]}]},{"target":{"name":"Calendric_unit","spans":[{"start":4,"end":5,"text":"day"}]},"annotationSets":[{"rank":0,"score":21.208065336877716,"frameElements":[{"name":"Unit","spans":[{"start":4,"end":5,"text":"day"}]},{"name":"Count","spans":[{"start":3,"end":4,"text":"one"}]}]}]},{"target":{"name":"Building_subparts","spans":[{"start":7,"end":8,"text":"cell"}]},"annotationSets":[{"rank":0,"score":15.787005035121469,"frameElements":[{"name":"Building_part","spans":[{"start":7,"end":8,"text":"cell"}]}]}]},{"target":{"name":"Relative_time","spans":[{"start":12,"end":13,"text":"subsequent"}]},"annotationSets":[{"rank":0,"score":18.54238681386274,"frameElements":[]}]}],"tokens":["Serum","biomarkers",",","one","day","after","CAR-T","cell","infusion",",","correlated","with","subsequent","sCRS","and","neurotoxicity","."]}
{"frames":[{"target":{"name":"Building_subparts","spans":[{"start":4,"end":5,"text":"cells"}]},"annotationSets":[{"rank":0,"score":17.965746537707037,"frameElements":[{"name":"Building_part","spans":[{"start":4,"end":5,"text":"cells"}]}]}]},{"target":{"name":"Communicate_categorization","spans":[{"start":7,"end":8,"text":"defined"}]},"annotationSets":[{"rank":0,"score":36.03148016487924,"frameElements":[{"name":"Item","spans":[{"start":8,"end":9,"text":"CD4"}]}]}]},{"target":{"name":"Permitting","spans":[{"start":17,"end":18,"text":"allowed"}]},"annotationSets":[{"rank":0,"score":15.881462420935078,"frameElements":[{"name":"State_of_affairs","spans":[{"start":18,"end":28,"text":"identification of correlative factors for CAR-T cell expansion , persistence"}]}]}]},{"target":{"name":"Contingency","spans":[{"start":21,"end":22,"text":"factors"}]},"annotationSets":[{"rank":0,"score":16.5662245580575,"frameElements":[{"name":"Determinant","spans":[{"start":21,"end":22,"text":"factors"}]}]}]},{"target":{"name":"Building_subparts","spans":[{"start":24,"end":25,"text":"cell"}]},"annotationSets":[{"rank":0,"score":15.991531133481066,"frameElements":[{"name":"Building_part","spans":[{"start":24,"end":25,"text":"cell"}]}]}]},{"target":{"name":"Expansion","spans":[{"start":25,"end":26,"text":"expansion"}]},"annotationSets":[{"rank":0,"score":41.604370202268036,"frameElements":[]}]},{"target":{"name":"Process_continue","spans":[{"start":27,"end":28,"text":"persistence"}]},"annotationSets":[{"rank":0,"score":35.67134350031895,"frameElements":[{"name":"Event","spans":[{"start":24,"end":25,"text":"cell"}]}]}]},{"target":{"name":"Cause_to_make_progress","spans":[{"start":38,"end":39,"text":"improved"}]},"annotationSets":[{"rank":0,"score":72.46223948849872,"frameElements":[{"name":"Project","spans":[{"start":39,"end":40,"text":"disease"}]}]}]},{"target":{"name":"Medical_conditions","spans":[{"start":39,"end":40,"text":"disease"}]},"annotationSets":[{"rank":0,"score":33.88193142037607,"frameElements":[]}]},{"target":{"name":"Response","spans":[{"start":40,"end":41,"text":"response"}]},"annotationSets":[{"rank":0,"score":34.97705125582059,"frameElements":[]}]},{"target":{"name":"Clothing","spans":[{"start":42,"end":43,"text":"overall"}]},"annotationSets":[{"rank":0,"score":34.58456035740788,"frameElements":[]}]},{"target":{"name":"Surviving","spans":[{"start":45,"end":46,"text":"survival"}]},"annotationSets":[{"rank":0,"score":14.62601581185001,"frameElements":[]}]}],"tokens":["Immunotherapy","with","CD19","CAR-T","cells","in","a","defined","CD4","-LRB-","+","-RRB-","/CD8","-LRB-","+","-RRB-","ratio","allowed","identification","of","correlative","factors","for","CAR-T","cell","expansion",",","persistence",",","and","toxicity",",","and","facilitated","optimization","of","lymphodepletion","that","improved","disease","response","and","overall","and","progression-free","survival","."]}
